-
Zhejiang Dian Diagnostics Partners with Meituan for Digital Healthcare Services Expansion
•
Zhejiang Dian Diagnostics Co., Ltd (SHE: 300244), a prominent medical diagnostics company based in China, has entered into a strategic partnership with Meituan, the country’s leading delivery giant, to explore new digital and intelligent medical and healthcare service models. The collaboration aims to leverage the strengths of both companies to…
-
Ocumension Therapeutics’ Zerviate NDA Accepted for Review by China’s NMPA
•
Ocumension Therapeutics (HKG: 1477), a leading Chinese ophthalmology specialist, has announced that the National Medical Products Administration (NMPA) has accepted for review the New Drug Application (NDA) for Zerviate (OT-1001), a histamine H1 receptor-targeted therapy. This development marks a significant step forward for the company in bringing this innovative treatment…
-
Pfizer and Sinopharm Expand Partnership to Enhance Drug Distribution and Lifecycle Solutions
•
US pharmaceutical giant Pfizer Inc. (NYSE: PFE) has announced a strategic partnership with China-based Sinopharm Group Co., Ltd (HKG: 1099). This collaboration expands on their existing relationship, which spans several years and includes activities in importing, distribution, outsourcing, retailing, and other areas. The partnership aims to leverage Sinopharm’s extensive logistics…
-
Fosun Pharmaceutical’s FCN-159 Earns Breakthrough Therapy Designation for Histiocyte Tumors
•
The Center for Drug Evaluation (CDE) website has announced that Shanghai Fosun Pharmaceutical (Group) Co., Ltd’s (SHA: 600196, HKG: 2196) novel small-molecule chemical drug FCN-159 has been granted breakthrough therapy designation (BTD) status for the treatment of histiocyte tumors. FCN-159’s Mechanism and ImpactFCN-159 is a highly selective MEK1/2 inhibitor with…
-
Aosaikang Pharmaceutical Receives NMPA Review for ASKC200 Liniment from Propella Therapeutics
•
Beijing Aosaikang Pharmaceutical Co., Ltd (SHE: 002755) has announced that the National Medical Products Administration (NMPA) has accepted for review its clinical trial approval filing for ASKC200, a liniment product in-licensed from US-based Propella Therapeutics, Inc. The primary indication for the product is the treatment of osteoarthritis pain. Product Rights…
-
HuidaGene Therapeutics Enhances CRISPR-Cas12f System with Higher Editing Efficiency
•
HuidaGene (Shanghai) Therapeutics Co., Ltd, a China-based biotechnology company, has made significant strides in the field of CRISPR-Cas genome editing technology. Through protein and sgRNA engineering, HuidaGene has enhanced the OsCas12f1 (enOsCas12f1) and enRhCas12f1 variants of the CRISPR-Cas12f system. These variants exhibit much higher editing efficiency and possess broader PAMs…
-
Shanghai’s PharmaLegacy Files for IPO on STAR, Targets Pre-clinical R&D Expansion
•
PharmaLegacy Laboratories (Shanghai) Co., Ltd., a Shanghai-based pre-clinical Contract Research Organization (CRO), has reportedly filed for an initial public offering (IPO) with the Shanghai Stock Exchange’s Sci-Tech Innovation Board (STAR). The company anticipates raising RMB 601 million (USD 87.8 million) in proceeds, which will be allocated towards the construction of…
-
Huadong Medicine Reports 9.12% YOY Revenue Growth and 13.24% Increase in Net Profits for 2022
•
Huadong Medicine Co., Ltd (SHE: 000963), a leading China-based pharmaceutical company, has released its 2022 financial report, demonstrating robust growth with revenues of RMB 37.715 billion (USD 5.5 billion), an increase of 9.12% year-on-year (YOY), and net profits of RMB 2.598 billion (USD 379.3 million), marking a 13.24% YOY increase.…
